The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Jul. 20, 2017
Applicants:

Fred Hutchinson Cancer Research Center, Seattle, WA (US);

The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA (US);

Inventors:

Irwin Bernstein, Seattle, WA (US);

Vincent Luca, Palo Alto, CA (US);

Kenan Christopher Garcia, Menlo Park, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 14/475 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 15/63 (2006.01); C12N 5/10 (2006.01); C07K 16/22 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); G01N 33/566 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/00 (2018.01); C07K 14/475 (2013.01); C07K 14/705 (2013.01); C07K 16/22 (2013.01); C07K 16/2896 (2013.01); C07K 16/46 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); G01N 33/566 (2013.01); G01N 33/574 (2013.01); C07K 14/70596 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/74 (2013.01);
Abstract

This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.


Find Patent Forward Citations

Loading…